Nivolumab: all 1,111 studies that test it

Page 3 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results posted
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaCompletedNCT04493203Phase 2Results posted
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal CancerTerminatedNCT04458909Phase 3Results posted
• Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
• Neoadjuvant Immunotherapy in Brain MetastasesTerminatedNCT04434560Phase 2Results posted
• Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 2Results posted
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results posted
• A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT04350463Phase 2Results posted
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results posted
• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results posted
• Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaActive, not recruitingNCT04339738Phase 2Results posted
• Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results posted
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted
• Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)CompletedNCT04282109Phase 2Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedNCT04209114Phase 3Results posted
• Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerCompletedNCT04208958Phase 1/2Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results posted
• A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/2Results posted
• VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)TerminatedNCT04166383Phase 2Results posted
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedNCT04159896Phase 2Results posted
• A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedNCT04149574Phase 3Results posted
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
• Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsActive, not recruitingNCT04126070Phase 2Results posted
• Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143CompletedNCT04122625Phase 1/2Results posted
• Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results posted
• Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT04118166Phase 2Results posted
• Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedNCT04109066Phase 3Results posted
• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCompletedNCT04100018Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedNCT04075604Phase 2Results posted
• Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)TerminatedNCT04057365Phase 2Results posted
• Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsCompletedNCT04056910Phase 2Results posted
• Nivolumab Combined With BMS-986253 in HCC PatientsTerminatedNCT04050462Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingNCT04025879Phase 3Results posted
• Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)Active, not recruitingNCT04021108Phase 2Results posted
• Nivolumab in Biochemically Recurrent dMMR Prostate CancerCompletedNCT04019964Phase 2Results posted
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results posted
• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results posted
• An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersCompletedNCT03994601Phase 1/2Results posted
• High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results posted
• A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal CancerCompletedNCT03981146Phase 2Results posted
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.CompletedNCT03980925Phase 2Results posted
• IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results posted
• Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedNCT03958045Phase 2Results posted
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerActive, not recruitingNCT03952585Phase 2/3Results posted
• De-Escalation Therapy for Human Papillomavirus Negative DiseaseCompletedNCT03944915Phase 2Results posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCompletedNCT03927105Phase 2Results posted
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results posted
• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3Results posted
• Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results posted
• Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerCompletedNCT03894891Phase 2Results posted
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNCompletedNCT03878979Phase 2Results posted
• Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT03854032Phase 2Results posted
• Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results posted
• Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedNCT03834623Phase 2Results posted
• Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerCompletedNCT03829722Phase 2Results posted
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• VAccination in Early and ADvanced Prostate caNCErTerminatedNCT03815942Phase 1/2Results posted
• Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerCompletedNCT03800602Phase 2Results posted
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results posted
• A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCompletedNCT03792750Phase 1/2Results posted
• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results posted
• A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedNCT03785925Phase 2Results posted
• Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerCompletedNCT03785873Phase 1/2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaTerminatedNCT03782064Phase 2Results posted
• Abemaciclib and Nivolumab for Subjects With Hepatocellular CarcinomaTerminatedNCT03781960Phase 2Results posted
• Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results posted
• Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedNCT03743766Phase 2Results posted
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03739619Phase 1/2Results posted
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3Results posted
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeActive, not recruitingNCT03718767Phase 2Results posted
• Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerCompletedNCT03715946Phase 2Results posted
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerCompletedNCT03711058Phase 1/2Results posted
• Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerCompletedNCT03697564Phase 2Results posted
• BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTerminatedNCT03695250Phase 1/2Results posted
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results posted
• Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaCompletedNCT03692325Phase 2Results posted
• Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaCompletedNCT03682276Phase 1/2Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03663166Phase 1/2Results posted
• Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung CancerTerminatedNCT03662074Phase 2Results posted
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedNCT03646461Phase 2Results posted
• Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerCompletedNCT03642067Phase 2Results posted
• Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyCompletedNCT03639935Phase 2Results posted
• Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerActive, not recruitingNCT03637543Phase 2Results posted
• A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedNCT03636477Phase 1Results posted
• Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)TerminatedNCT03634800Phase 2Results posted
• Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyTerminatedNCT03631641Phase 2Results posted
• CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseCompletedNCT03618641Phase 2Results posted

← Nivolumab overview